FDA approved Epkinly (epcoritamab-bysp) for the treatment of adults with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.
FDA granted traditional approval to Merck’s pembrolizumab (Keytruda) with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 (CPS ≥1).
